文献速递基础与转化研究新药、器械与细胞基因治疗研发

β-珠蛋白基因矫正人造血干细胞治疗镰状细胞病的临床前研究

Development of β-globin gene correction in human hematopoietic stem cells as a potential durable treatment for sickle cell disease.
PubMed 文献 · Sci Transl Med · 2021-01-01

该研究在健康供者和镰状细胞病患者来源的CD34+细胞中开展CRISPR-Cas9联合rAAV6介导的HBB基因矫正,临床规模生产实现高达60%的等位基因矫正,移植免疫缺陷小鼠后获得20%基因矫正及多系植入,长期安全性研究未发现异常造血、基因毒性或致瘤性。

要点

  • 临床规模生产可实现高达60%的HBB等位基因矫正。
  • 移植NSG小鼠后获得20%基因矫正并实现多系植入。
  • 长期安全性研究未发现异常造血、基因毒性或致瘤性。

核心结论

  • 临床前数据支持该基因矫正策略的安全性、有效性和可重复性,可启动SCD患者的1/2期临床试验。

研究设计与样本

  • 临床前研究,在健康供者和SCD患者来源的plerixafor动员CD34+细胞中开展CRISPR-Cas9联合rAAV6介导的HBB基因矫正(gcHBB-SCD)。
  • 开展临床规模gcHBB-SCD生产、免疫缺陷NSG小鼠移植及长期安全性、致瘤性和毒理学研究。

主要发现

  • 临床规模gcHBB-SCD生产实现高达60%的HBB等位基因矫正。
  • 移植免疫缺陷NSG小鼠后获得20%基因矫正并实现多系植入。
  • 长期安全性、致瘤性和毒理学研究未发现异常造血、基因毒性或致瘤性证据。

关键数值与推荐

  • 临床规模gcHBB-SCD生产实现高达60%的HBB等位基因矫正。
  • 移植NSG小鼠后获得20%基因矫正并实现多系植入。

临床怎么用

  • 该自体HSPC体外β-珠蛋白基因矫正策略在临床前显示安全有效,支持推进SCD患者1/2期临床试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Sickle cell disease (SCD) is the most common serious monogenic disease with 300,000 births annually worldwide. SCD is an autosomal recessive disease resulting from a single point mutation in codon six of the β-globin gene (HBB). Ex vivo β-globin gene correction in autologous patient-derived hematopoietic stem and progenitor cells (HSPCs) may potentially provide a curative treatment for SCD. We previously developed a CRISPR-Cas9 gene targeting strategy that uses high-fidelity Cas9 precomplexed with chemically modified guide RNAs to induce recombinant adeno-associated virus serotype 6 (rAAV6)-mediated HBB gene correction of the SCD-causing mutation in HSPCs. Here, we demonstrate the preclinical feasibility, efficacy, and toxicology of HBB gene correction in plerixafor-mobilized CD34+ cells from healthy and SCD patient donors (gcHBB-SCD). We achieved up to 60% HBB allelic correction in clinical-scale gcHBB-SCD manufacturing. After transplant into immunodeficient NSG mice, 20% gene correction was achieved with multilineage engraftment. The long-term safety, tumorigenicity, and toxicology study demonstrated no evidence of abnormal hematopoiesis, genotoxicity, or tumorigenicity from the engrafted gcHBB-SCD drug product. Together, these preclinical data support the safety, efficacy, and reproducibility of this gene correction strategy for initiation of a phase 1/2 clinical trial in patients with SCD.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Lattanzi A, Camarena J, Lahiri P, et al. Development of β-globin gene correction in human hematopoietic stem cells as a potential durable treatment for sickle cell disease. Sci Transl Med. 2021. PMID: 34135108. doi:10.1126/scitranslmed.abf2444

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。